Company news
Tuhura Biosciences, Inc. (NASDAQ:HURA) news
Every Tuhura Biosciences, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody...
September 14, 2026
TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
August 14, 2026
TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
July 22, 2026
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Def...
June 15, 2026
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 15, 2026
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
May 12, 2026
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028
April 22, 2026
TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations
April 7, 2026
TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
April 1, 2026
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and othe...
March 23, 2026
TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
February 27, 2026
TuHURA Biosciences Announces Participation in Upcoming Investor Conferences
February 24, 2026
TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
February 17, 2026
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 12, 2026
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
February 2, 2026
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Ach...
December 15, 2025
TuHURA Biosciences Provides Corporate Update Following Recent Financing
December 11, 2025
TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering
December 9, 2025
TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immun...
December 8, 2025
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
November 14, 2025
TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) ...
November 3, 2025
TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
August 20, 2025
TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
August 14, 2025
TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
July 1, 2025
TuHURA Biosciences Completes Acquisition of Kineta
June 30, 2025
TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in F...
June 24, 2025
TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
June 23, 2025
FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel ...
June 9, 2025
TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise ...
June 3, 2025
TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting
June 2, 2025
TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
May 15, 2025
TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference
May 13, 2025
TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Tre...
May 5, 2025
TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Resp...
April 28, 2025
TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting
April 8, 2025
TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and ...
April 7, 2025
TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
April 1, 2025
TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Med...
March 11, 2025
TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference
March 10, 2025
TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
February 19, 2025
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
December 12, 2024
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First ...
November 25, 2024
TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in P...
August 19, 2024
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inh...
July 8, 2024
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 Novel anti-VISTA Checkpoint Inh...
July 8, 2024
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine...
June 3, 2024
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine...
June 3, 2024
Kintara Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference
May 8, 2023
Kintara Therapeutics to Present at the 2023 BIO CEO & Investor Conference
January 30, 2023